Sotatercept, a novel transforming growth factor beta ligand trap, improves anemia in beta-thalassemia: a phase 2, open-label, dose-finding study by M.D. Cappellini et al.
Sotatercept, a novel transforming growth factor beta ligand trap,
improves anemia in beta-thalassemia: a phase 2, open-label,
dose-finding study
by Maria Domenica Cappellini, John Porter, Raffaella Origa, Gian Luca Forni, Ersi Voskaridou,
Frédéric Galactéros, Ali T. Taher, Jean-Benoît Arlet, Jean-Antoine Ribeil, Maciej Garbowski,
Giovanna Graziadei, Chantal Brouzes, Michaela Semeraro, Abderrahmane Laadem, Dimana
Miteva, Jun Zou, Victoria Sung, Tatiana Zinger, Kenneth M. Attie, and Olivier Hermine 
Haematologica 2018 [Epub ahead of print]
Citation: Maria Domenica Cappellini, John Porter, Raffaella Origa, Gian Luca Forni, Ersi Voskaridou, 
Frédéric Galactéros, Ali T. Taher, Jean-Benoît Arlet, Jean-Antoine Ribeil, Maciej Garbowski, 
Giovanna Graziadei, Chantal Brouzes, Michaela Semeraro, Abderrahmane Laadem, Dimana Miteva, 
Jun Zou, Victoria Sung, Tatiana Zinger, Kenneth M. Attie, and Olivier Hermine. Sotatercept, a novel 
transforming growth factor beta ligand trap, improves anemia in beta-thalassemia: a phase 2, open-label,
dose-finding study. Haematologica. 2018; 103:xxx
doi:10.3324/haematol.2018.198887
Publisher's Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science.
Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that
have completed a regular peer review and have been accepted for publication. E-publishing
of this PDF file has been approved by the authors. After having E-published Ahead of Print,
manuscripts will then undergo technical and English editing, typesetting, proof correction and
be presented for the authors' final approval; the final version of the manuscript will then
appear in print on a regular issue of the journal. All legal disclaimers that apply to the
journal also pertain to this production process.
 Copyright 2018 Ferrata Storti Foundation.
Published Ahead of Print on October 18, 2018, as doi:10.3324/haematol.2018.198887.
1 
Sotatercept, a novel transforming growth factor beta ligand trap, improves anemia in 
beta-thalassemia: a phase II, open-label, dose-finding study 
 
Maria Domenica Cappellini,1 John Porter,2 Raffaella Origa,3 Gian Luca Forni,4 Ersi 
Voskaridou,5 Frédéric Galactéros,6 Ali T. Taher,7 Jean-Benoît Arlet,8,9,10 Jean-Antoine Ribeil,11 
Maciej Garbowski,2 Giovanna Graziadei,1 Chantal Brouzes,11 Michaela Semeraro,11 
Abderrahmane Laadem,12 Dimana Miteva,13 Jun Zou,12 Victoria Sung,14 Tatiana Zinger,13 
Kenneth M. Attie15 and Olivier Hermine.9,10,16 
 
1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Department of Clinical 
Sciences and Community Health, University of Milan, Milan, Italy 
2Department of Haematology, University College London, London, UK 
3Day Hospital Talassemia, Ospedale Pediatrico Microcitemico “A.Cao”, A.O. “G. Brotzu”, 
Cagliari, Italy 
4Centro della Microcitemia, Ospedali Galliera, Genova, Italy 
5Thalassaemia Centre, Laikon General Hospital, Athens, Greece 
6UMGGR, Hôpital Henri Mondor; Assistance Publique-Hôpitaux de Paris (APHP); UPEC, 
Créteil, France 
7Department of Internal Medicine, American University of Beirut Medical Center, Beirut, 
Lebanon 
8Department of Internal Medicine, APHP, Hôpital Européen Georges-Pompidou, Paris, 
France 
9INSERM UMR1163, CNRS ERL 8254, Institut Imagine, Université Paris Descartes-
Sorbonne Paris Cité, Paris, France 
10Laboratory of Excellence GR-Ex, Paris, France 
11Laboratory of Onco-hematology, Hôpital Necker-Enfants Malades, Paris, France 
12Celgene Corporation, Summit, NJ, USA 
13Celgene Corporation, Boudry, Switzerland 
2 
14Celgene Corporation, San Francisco, CA, USA 
15Acceleron Pharma, Cambridge, MA, USA 
16Department of Hematology, APHP, Hôpital Necker, Paris, France 
 
Correspondence: Prof Maria Cappellini, e-mail: maria.cappellini@unimi.it.  
Or Prof Olivier Hermine, e-mail: olivier.hermine@nck.aphp.fr. 
 
These data were presented at the 20th Meeting of the European Hematology Association in 
Vienna, Austria, June 11–14, 2015. 
 
Running title: Sotatercept TGF-β ligand trap in β-thalassemia 
Text word count: 3082 (max. 4000) 
Abstract word count: 246 (max. 250) 
Tables/Figures: 5 (max. 8) 
References: 28 (max. 100) 
Supplemental file: 1 (max. 1) 
Trial registration: clinicaltrials.gov identifier: NCT01571635. 
Acknowledgments: The authors would like to thank all the patients and their families who 
participated in this study. The authors received editorial and writing support from Victoria 
Edwards, PhD, from Excerpta Medica, funded by Celgene Corporation. 
Celgene Corporation and Acceleron Pharma provided funding for this study.  
  
3 
Abstract  
 
β-thalassemia, a hereditary blood disorder caused by defective synthesis of hemoglobin 
β-globin chains, leads to ineffective erythropoiesis and chronic anemia that may require 
blood transfusions. Sotatercept (ACE-011) acts as a ligand trap to inhibit negative regulators 
of late-stage erythropoiesis in the transforming growth factor beta superfamily, correcting 
ineffective erythropoiesis. In this phase II, open-label, dose-finding study, 16 patients with 
transfusion-dependent β-thalassemia and 30 patients with non-transfusion-dependent 
β-thalassemia were enrolled at 7 centers in 4 countries from November 2012 to November 
2014. Patients were treated with sotatercept at 0.1, 0.3, 0.5, 0.75, or 1.0 mg/kg to determine 
a safe and effective dose. Doses were administered by subcutaneous injection every 3 
weeks. Patients were treated for ≤22 months. Response was assessed as a ≥20% reduction 
in transfusion burden sustained for 24 weeks in transfusion-dependent β-thalassemia 
patients, and an increase in hemoglobin level of ≥1.0 g/dL sustained for 12 weeks in non-
transfusion-dependent β-thalassemia patients. Sotatercept was well tolerated. After a 
median treatment duration of 14.4 months (range 0.6-35.9), no severe life-threatening 
adverse events were observed; 13% of patients reported serious but manageable adverse 
events. The active dose of sotatercept was ≥0.3 mg/kg for non-transfusion-dependent β-
thalassemia and ≥0.5 mg/kg for transfusion-dependent β-thalassemia patients. Of 30 non-
transfusion-dependent β-thalassemia patients treated with ≥0.1 mg/kg sotatercept, 18 (60%) 
achieved a mean hemoglobin increase ≥1.0 g/dL, and 11 (37%) an increase ≥1.5 g/dL, 
sustained for ≥12 weeks. Four (100%) transfusion-dependent β-thalassemia patients treated 
with 1.0 mg/kg sotatercept achieved a transfusion-burden reduction of ≥20%. Sotatercept 
was effective and well tolerated in patients with β-thalassemia. Most non-transfusion-
dependent β-thalassemia patients treated with higher doses achieved sustained increases in 
hemoglobin level. Transfusion-dependent β-thalassemia patients treated with higher doses 
of sotatercept achieved notable reductions in transfusion requirement.  
The registration number at ClinicalTrials.gov was NCT01571635. 
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Introduction 
β-thalassemia is a hereditary blood disorder caused by defective synthesis of the 
β-globin chains of hemoglobin (Hb)1 characterized by ineffective erythropoiesis.2-4 Mutations 
in the β-globin genes lead to reduced or absent β-globin chain synthesis, increasing the ratio 
of α-globin to non-α-globin chains. Due to the relative excess of α-globin chains, α-globin 
precipitates within erythroblasts as hemichromes, leading to oxidative stress, maturation 
arrest, membrane damage and apoptosis of late-stage erythroid precursors, and reduced 
red blood cell (RBC) life span.4-6 Although erythropoiesis-stimulating agents (ESAs) have 
been used in patients with β-thalassemia, ineffective erythropoiesis is not corrected.7 Use of 
ESAs is, therefore, not recommended for the treatment of β-thalassemia.7,8 
 
β-thalassemia phenotypes vary in severity, ranging from asymptomatic thalassemia 
minor to non-transfusion-dependent thalassemia (NTDT) (including thalassemia intermedia 
and Hb E-beta thalassemia) to transfusion-dependent thalassemia (TDT) (thalassemia 
major). Treatment of TDT involves regular and lifelong blood transfusions leading to iron 
overload; long-term management of iron overload requires regular iron chelation therapy 
(ICT).9,10 However, ICT is associated with significant toxicities and requires a high level of 
treatment adherence and monitoring that can be difficult to manage and may negatively 
impact patient quality of life.11,12 Bone marrow transplantation offers potentially curative 
treatment,13 but is not possible in all patients,14 and is associated with significant morbidity 
and mortality.15 Gene therapy has shown early promise but is still under investigation.16 
NTDT treatment is based on managing the long-term complications of ineffective 
erythropoiesis, including chronic anemia and iron overload,17 using ICT and occasional RBC 
transfusion.18,19 
 
Sotatercept is a ligand trap that inhibits transforming growth factor beta (TGF-β) 
superfamily members including growth differentiation factor 11 (GDF-11) and activin B.20,21 
GDF-11 is overexpressed in immature erythroblasts in β-thalassemia.21 Aberrant GDF-11 
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production may induce expansion of erythroid progenitors and increase oxidative stress, 
leading to maturation arrest of late erythroid precursors and ineffective erythropoiesis.21 
Preclinical work has shown that administration of an activin receptor IIA (ActRIIA) ligand trap 
decreases GDF-11 concentration, reduces reactive oxidative stress levels, and promotes 
terminal maturation in immature erythroblasts.21 Sotatercept is a novel recombinant fusion 
protein consisting of the extracellular domain of the human ActRIIA (ACVR2A) linked to the 
human immunoglobulin G1 Fc domain.20 When administered subcutaneously, sotatercept 
increased Hb levels and RBC count in healthy, postmenopausal women.22 In a phase II trial 
of patients with lower-risk myelodysplastic syndromes (MDS) and anemia, sotatercept 
reduced transfusion burden in 47% of patients with a high transfusion burden, and increased 
Hb levels in 58% of patients with a low transfusion burden.23 In a β-thalassemia mouse 
model, RAP-011 (a murine analog of sotatercept) improved hematologic parameters 
including RBC count, total Hb, hematocrit, and mean corpuscular volume.21 
 
The aim of this phase II study was to determine a safe, tolerable, and effective dose of 
sotatercept to increase Hb levels and reduce blood transfusion burden in adults with TDT 
and NTDT β-thalassemia. 
 
Methods 
In this phase II, open-label, dose-finding study, patients were enrolled at 7 centers in 
France, Greece, Italy, and the United Kingdom (listed in the Online Supplemental Data) from 
November 2012 to November 2014. The study was approved by individual institutional 
review boards at participating centers and, where appropriate, national health authorities, 
and was conducted in compliance with the Declaration of Helsinki. All patients provided 
written informed consent. The ClinicalTtrials.gov registration number is NCT01571635. 
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Inclusion criteria 
Eligible patients were aged ≥18 years with a diagnosis of TDT or NTDT, and an Eastern 
Cooperative Oncology Group performance status of 0 to 1. Transfusion dependence was 
defined as receiving ≥2 RBC units every 30 days for ≥168 days prior to study enrollment, 
with no transfusion-free period of >45 consecutive days during this period. Mean Hb level 
prior to transfusion was ≤10.5 g/dL in the 168 days prior to enrollment, with the last 
pretransfusion Hb level preceding enrollment being ≤10.5 g/dL. 
 
Non-transfusion dependence was defined as ≤1 episode of transfusion during the 168 
days prior to enrollment; an episode of transfusion was defined as ≤4 RBC units received 
during the 168 days prior to enrollment. Exclusion criteria are listed in the Online 
Supplemental Data. 
 
Study design 
To determine a safe and tolerable dose of sotatercept, a dose-escalation study was 
carried out. Patients were initially enrolled in 2 cohorts, receiving doses of 0.1 mg/kg and 
0.3 mg/kg, administered by subcutaneous injection every 3 weeks. Four dose-escalation 
cohorts, with doses of 0.5, 0.75, 1.0, and 1.5 mg/kg, were subsequently opened to 
enrollment. Details of the study design are included in the Online Supplemental Data. 
 
Study end points 
Primary efficacy end points were a reduction in transfusion burden of ≥20% from 
pretreatment levels, sustained for 24 weeks in TDT patients, and an increase in Hb level of 
≥1.0 g/dL sustained for 12 weeks from mean pretreatment Hb levels in NTDT patients. 
Hematologic parameters, including Hb levels and RBC counts, were measured on days 1, 8, 
and 15 (±3 days) of each 3-week sotatercept dose period. Secondary end points included 
reduction in RBC transfusion burden in TDT patients, Hb level increase from baseline in 
NTDT patients, and safety. Exploratory end points included iron metabolism markers 
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(including serum ferritin [SF] and hepcidin), and clinical symptoms associated with ineffective 
erythropoiesis and anemia (including extramedullary hematopoiesis, leg ulcers, and bilirubin 
levels). 
 
Statistical analysis 
Efficacy analyses were carried out on the intent-to-treat population, which included all 
patients enrolled for treatment. Efficacy data are presented by assigned dose group. Safety 
analyses were conducted on the safety population, defined as those patients who received 
≥1 dose of sotatercept. Safety data are presented prior to intrapatient dose escalation for 
sotatercept dose groups and presented post-intrapatient dose escalation for patients overall. 
The data cutoff date for this analysis was November 27, 2015. Detailed statistical methods 
are included in the Online Supplemental Data. 
 
Results 
Patients 
As of November 27, 2015, 46 patients had been enrolled from November 2012 to 
November 2014 – 16 with TDT and 30 with NTDT (Online Supplemental Figure S1). 
Baseline demographic and disease characteristics are shown (Table 1); data are presented 
by assigned dose level of sotatercept prior to dose escalation. All patients received ≥2 doses 
of sotatercept. Median duration of treatment was 19.6 months (range, 0.6-35.9) for NTDT 
patients and 13.8 months (range, 1.4-27.7) for TDT patients. 
 
Erythroid response  
NTDT patients 
Of the 30 patients with NTDT treated with sotatercept doses of 0.1 to 1.0 mg/kg, 
18 (60%) achieved a mean Hb increase of ≥1.0 g/dL, and 11 (37%) had a mean Hb increase 
of ≥1.5 g/dL sustained for ≥12 weeks (Figure 1A). The highest rate of response was seen 
with 0.75 mg/kg sotatercept (86% [6 of 7] patients achieved an Hb increase of ≥1.5 g/dL). 
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Responders receiving sotatercept 0.5 mg/kg experienced the greatest maximum increase in 
Hb levels within 12 weeks from baseline (3.2±0.2 g/dL) (Figure 1B). No patients receiving 
sotatercept 0.1 mg/kg achieved a response. 
 
Mean change in Hb levels from baseline in NTDT patients is shown (Figure 2). No 
significant differences in reticulocyte count and fetal hemoglobin (HbF) levels were reported 
for NTDT patients during the study (data not shown). The starting active dose of sotatercept 
in patients with NTDT, based on the observed responses, was ≥0.3 mg/kg. 
 
Of 4 patients with NTDT receiving concomitant hydroxyurea therapy at enrollment, 3 
continued to receive hydroxyurea during the study (dose range 54-84) without interruption or 
modification; 2 achieved a mean Hb increase of ≥1 g/dL sustained for ≥12 weeks. 
 
TDT patients 
Of 16 patients with TDT treated with sotatercept, 10 (63%) achieved transfusion burden 
reduction of ≥20% sustained for ≥24 weeks; 7 patients (44%) achieved a reduction of ≥33%, 
and 2 patients (13%), a reduction of ≥50% (Figure 3). Five of the 10 patients achieved 
transfusion burden reduction while maintaining stable or improved Hb levels at 12 weeks. 
The mean change in Hb level from baseline to the end of treatment was 0.7 g/dL in all 
patients with TDT. Nine patients (56%) achieved a reduction in transfusion frequency over 
24 weeks, receiving fewer transfusions per 24 weeks during treatment, while maintaining 
stable or improved Hb levels over pretransfusion levels. Four patients (25%) also achieved a 
reduction in transfusion frequency over 24 weeks; however, Hb levels were lower compared 
with pretransfusion levels. The remaining 3 (19%) patients (2 receiving 0.75 mg/kg 
sotatercept, 1 receiving 0.3 mg/kg sotatercept) experienced an increase in transfusion 
frequency, requiring between 0.7-1.0 additional transfusions per 24 weeks, representing an 
increase of 6.7-17.2% from baseline. The active starting dose of sotatercept in patients with 
TDT, based on the observed responses, was ≥0.5 mg/kg. 
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Bilirubin 
For NTDT patients, indirect bilirubin and total bilirubin decreased by 5-25% for patients 
receiving 0.3, 0.75, and 1.0 mg/kg (Online Supplemental Figure S2A). Among TDT patients 
with available bilirubin data at baseline, indirect bilirubin and total bilirubin increased by 
15-80% during treatment from baseline, at all dose levels (Online Supplemental Figure S2B). 
However, the changes were not statistically significant, and there was wide variability in the 
level of change. 
 
Clinical response 
Extramedullary masses 
The effect of sotatercept on extramedullary masses (EMM) as measured by MRI was 
reported for 4 patients with NTDT and 1 with TDT. The TDT patient experienced a reduction 
in EMM volume at 12 months posttreatment with sotatercept 0.75 mg/kg (data not shown); 
however, due to unequal distribution of the mass, estimation of the exact volume was not 
possible. One NTDT patient experienced reduction in EMM volume at 12 months 
posttreatment with sotatercept 0.3 mg/kg ranging from 0.4% to 59.3% across 3 separate 
EMM (Online Supplemental Figure S3A), alongside a stable increase in Hb level. Another 
NTDT patient treated with sotatercept 1.0 mg/kg experienced volume increases of 67% and 
55% in 2 EMM, at 7 months posttreatment (Online Supplemental Figure S3B). This 
correlated with an increase in Hb levels (6 g/dL at baseline versus 8 g/dL at 7 months 
posttreatment). Two NTDT patients experienced a change in EMM volume of between 
−6.3% and +22.5% at 11 months posttreatment with sotatercept 1.0 mg/kg (data not shown). 
 
Leg ulcers 
Seven NTDT patients had a history of leg ulcers at baseline; the effect of sotatercept on 
chronic leg ulcers was reported for 1 NTDT patient. The chronic leg ulcers improved, and the 
dischromic area was reduced following treatment with sotatercept 0.5 mg/kg for 6 months 
(Online Supplemental Figure S4). 
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RBC morphology 
Changes to RBC morphology were recorded for all patients during the study. 
Representative images of the changes observed are provided (Online Supplemental Figure 
S5). Reduction in hypochromia, anisocytosis, and poikilocytosis, and the proportion of target 
cells were reported, and were associated with increased Hb levels. 
 
Serum ferritin 
Among NTDT patients who responded to sotatercept treatment, mean levels of SF 
decreased regardless of ICT status (Online Supplemental Figure S6 A-B). In contrast to 
NTDT patients, all TDT patients received ICT. Levels of SF decreased over time in TDT 
patients (Online Supplemental Figure S6C). 
 
Safety 
Twenty-five of 46 patients (54%) experienced ≥1 treatment-related adverse event (AE); 
the most common treatment-related AEs in all patients were bone pain (26% [n=12]), 
arthralgia (15% [n=7]), back pain (11% [n=5]), asthenia/fatigue (11% [n=5]), and 
hypertension (11% [n=5]) (Table 2). Treatment-related AEs led to discontinuation in 8 
patients (17%) (Table 2); of these 8 patients, 7 were NTD and 1 was TD. 
 
All 46 patients experienced ≥1 treatment-emergent AE (Online Supplemental Table S1); 
6 (13%) experienced ≥1 serious AE (Online Supplemental Table S2). Nine patients (20%) 
experienced ≥1 grade 3-4 treatment-emergent AE; hypertension and anemia were the most 
frequent (4% [n=2]) (Online Supplemental Table S3). Incidences of anemia were not related 
to treatment with sotatercept and resolved within 1 treatment cycle. 
 
The most common treatment-emergent AEs of any grade among the 30 NTDT patients 
were headache (53% [n=16]), arthralgia (47% [n=14]), cough (40% [n=12]), and 
asthenia/fatigue (37% [n=11]) (Online Supplemental Table S4).  
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The most common treatment-emergent AEs among the 16 TDT patients were bone pain 
(63% [n=10]), back pain (56% [n=9]), asthenia/fatigue (56% [n=9]), headache (44% [n=7]), 
and arthralgia (44% [n=7]) (Online Supplemental Table S4). Most treatment-emergent AEs 
were mild and did not lead to treatment discontinuation (Table 2). 
 
Bone pain was equally reported among sotatercept dose cohorts; mean time to first 
onset of bone pain was similar between dose cohorts, and the duration of bone pain was 
short (mean 12.0 days). 
 
Asthenia was less frequent at higher dose levels; 13% (3 incidences/23 doses received) 
versus 5% (4 incidences/81 doses received) for TDT patients and 36% (47 incidences/132 
doses received) versus 5% (3 incidences/67 doses received) for NTDT patients at 0.1 mg/kg 
and 1.0 mg/kg, respectively) (data not shown). 
 
Observed differences between baseline and on-treatment laboratory values for liver and 
kidney function, including alanine aminotransferase, aspartate aminotransferase, and serum 
creatinine levels, were within the ranges expected for this population and were not treatment 
related (data not shown). 
 
Dose delays for safety reasons were reported in 8 patients, all with NTDT. 
 
Discussion 
β-thalassemia is characterized by chronic anemia due to ineffective erythropoiesis and 
peripheral hemolysis. The current treatment for TDT is demanding, requiring regular blood 
transfusions and lifelong ICT. No standardized treatment for NTDT is available, and no 
treatment is currently available to improve ineffective erythropoiesis. Previous investigatory 
treatments for NTDT have included HbF modulators such as butyrates, azacitidine, or 
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hydroxyurea, with or without erythropoietin; however, results with these and other 
modulators of HbF have been inconsistent.24,25 
 
Sotatercept, a recombinant fusion protein that acts as a ligand trap for TGF-β 
superfamily ligands, is hypothesized to improve late-stage erythropoiesis by reducing 
proliferation of early erythroid progenitors and precursors while increasing differentiation and 
maturation of late-stage RBC precursors.20,21 This drug may therefore present a novel 
approach to restoring effective erythropoiesis in β-thalassemia. 
 
In this phase II, open-label, dose-finding study, sotatercept exhibited a good safety 
profile, and was tolerated by most patients. The most frequent AEs were bone, articular or 
back pain, and asthenia/fatigue. Discontinuations due to AEs were rare, and the incidence of 
grade 3-4 AEs was low. Changes in laboratory values for liver and kidney function were not 
thought to be treatment-related and were in line with fluctuations seen in β-thalassemia 
patients without treatment. The active dose of sotatercept was ≥0.3 mg/kg for NTDT and 
≥0.5 mg/kg for TDT patients. Importantly, concomitant administration of hydroxyurea did not 
appear to interfere with response to sotatercept, or with treatment compliance. 
 
The majority (75%) of NTDT patients treated with higher doses (0.75-1.0 mg/kg) of 
sotatercept achieved sustained increases in Hb of ≥1.0 g/dL. Similarly, 66% of TDT patients 
treated with higher doses of sotatercept (0.75-1.0 mg/kg) achieved reductions of ≥33% in 
RBC transfusion requirement. Hb increase and RBC transfusion reduction correlated with 
increased serum exposure to sotatercept (data not shown), although responses were not 
proportional to sotatercept dose due to interpatient variability in serum drug exposure. The 
small number of patients in each dose group makes comparison between sotatercept levels 
difficult. Studies are ongoing to identify any differences in baseline characteristics between 
responders and non-responders. 
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Ineffective erythropoiesis in β-thalassemia is associated with increased iron absorption, 
and patients with TDT often require regular RBC transfusions, further increasing the risk of 
iron overload. Reducing ineffective erythropoiesis and transfusion burden will decrease the 
rate of iron loading and associated complications such as heart, liver, and endocrine 
disorders. In this study, reduced SF levels were observed in sotatercept-treated patients with 
NTDT and TDT in a dose-dependent manner, regardless of concurrent treatment with ICT. 
Although these results suggest that sotatercept may reduce iron absorption by reducing 
ineffective erythropoiesis, other mechanisms such as removal or redistribution of iron from 
overloaded organs may also contribute to reduced iron levels. Further studies will be 
required to elucidate the mechanism of action; however, reduction in iron overload with long-
term use may translate into improved patient outcomes. 
 
Sotatercept treatment was associated with a reduction in the volume of EMM in 2 
patients with recorded data – 1 with NTDT and 1 with TDT – as measured by MRI. However, 
this change in EMM volume was not observed for all patients, and, due to technical 
difficulties, precise estimation of EMM volume was not always possible. Reduction in EMM 
did not appear to correlate with response. Further study is needed to determine the effect of 
sotatercept on EMM.  
 
In rodent models, sotatercept acts on ineffective erythropoiesis to reduce production of 
α-globin aggregates and apoptosis of late erythroid precursors, thereby increasing the 
efficiency of RBC production and Hb levels.21,26 Although Hb levels increased in NTDT 
patients during the study, no significant differences in HbF or reticulocyte count were 
reported. In a small subset of patients, normalization of RBC morphology was reported and 
associated with increasing Hb levels over time. These data suggest that sotatercept may 
increase the lifespan of RBCs in part by improving reticulocyte quality. These changes are 
consistent with the mode of action of sotatercept as a ligand trap for TGF-β superfamily 
members, including GDF-11. Binding of sotatercept to GDF-11 inhibits SMAD2/3 signaling, 
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reducing TGF-β superfamily ligand signaling and thereby promoting terminal differentiation 
of erythroblasts.20  
 
There are some limitations to this study, notably the small number of patients enrolled, 
which limited the ability to draw comparisons between different sotatercept dose groups. The 
inclusion of both NTDT and TDT β-thalassemia patients also resulted in patients being 
grouped into smaller subgroups that further limit the scope of the study, especially as 
intrapatient dose escalation was allowed. The short duration of follow-up may also be a 
limitation, and longer-term follow-up would provide information on the long-term clinical 
efficacy and safety of sotatercept.  
 
This study demonstrated the safety and efficacy of sotatercept in patients with 
β-thalassemia. Improvement in Hb levels and reduction in transfusion burden with 
sotatercept treatment has also been demonstrated in a phase II study of anemia patients 
with lower-risk MDS. 23 This suggests that sotatercept may work to decrease ineffective 
erythropoiesis in multiple disease states via a single underlying mode of action. Preliminary 
data with sotatercept led to the initiation of a similar phase II study in β-thalassemia of the 
related recombinant fusion protein, luspatercept. Luspatercept has more selective activity on 
GDF-11, and is also safe and effective in the treatment of β-thalassemia (Piga A, Perrotta S, 
Gamberini MR, Voskaridou E, Melpignano A, Filosa A, Caruso V, Pietrangelo A, Longo F, 
Tartaglione I, Borgna-Pignatti C, Zhang X, Laadem A, Sherman M, and Attie KM, manuscript 
submitted) and MDS.27 Luspatercept is comprised of the modified extracellular domain of 
human ActRIIB linked to the human IgG Fc domain,26,28 and has a similar mode of action to 
sotatercept but does not bind to other members of the TGF-β superfamily, such as activin 
A.20,26 A double-blind, randomized, placebo-controlled phase III trial of luspatercept in 
patients who require regular RBC transfusions due to β-thalassemia has recently completed 
recruitment (BELIEVE; NCT02604433). Luspatercept is also being studied in a phase III trial 
of patients with very low-, low- and intermediate-risk MDS (MEDALIST; NCT02631070). 
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While the decision was made not to advance trials of sotatercept in β-thalassemia due to 
binding of sotatercept to activin A, sotatercept represents the first drug developed in its 
class, functioning as a TGF-β superfamily inhibitor to correct ineffective erythropoiesis. 
TGF-β superfamily inhibition may provide an alternative or complementary treatment option 
for patients with β-thalassemia. 
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Table 1. Baseline characteristics for NTDT and TDT patients treated with sotatercept by assigned dose level. 
Characteristic 
Sotatercept dose  
0.1 mg/kg 
(n=8) 
0.3 mg/kg 
(n=9) 
0.5 mg/kg 
(n=8) 
0.75 mg/kg 
(n=12) 
1.0 mg/kg 
(n=9) 
Overall 
(N=46) 
NTDT patients n=6 n=6 n=6 n=7 n=5 n=30 
Age, years 
  Median  
 
39.5 
 
47.0 
 
39.0 
 
43.0 
 
41.0 
 
42.0 
  Range 32.0-53.0 37.0-55.0 34.0-54.0 29.0-65.0 19.0-52.0 19.0-65.0 
Female, n (%) 3 (50) 3 (50) 3 (50) 6 (86) 1 (20) 16 (53) 
Weight, kg       
  Median 54.0 58.0 64.2 56.0 62.0 58.9 
  Range 48.0-85.0 53.6-65.0 41.0-75.0 47.6-75.0 56.0-67.0 41.0-85.0 
Hb, g/dL 
  Median 
 
8.8 
 
8.5 
 
8.5 
 
8.7 
 
7.6 
 
8.4 
  Range 
  Mean±SD 
5.9-10.7 
8.6±1.68 
6.0-9.5 
8.3±1.26 
6.4-9.3 
8.2±1.13 
7.1-9.6 
8.5±0.89 
6.6-9.4 
7.7±1.04 
5.9-10.7 
8.3±1.18 
MCV, fL 
  Mean 
 
76.2 
 
75.6 
 
75.5 
 
63.2 
 
78.6 
 
73.3 
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Characteristic 
Sotatercept dose  
0.1 mg/kg 
(n=8) 
0.3 mg/kg 
(n=9) 
0.5 mg/kg 
(n=8) 
0.75 mg/kg 
(n=12) 
1.0 mg/kg 
(n=9) 
Overall 
(N=46) 
  Median  75.8 75.8 68.4 61.1 80.3 72.1 
  Range 67.7-83.8 61.6-90.5 62.6-103.4 54.6-80.4 70.6-89.3 54.6-103.4 
TDT patients n=2 n=3 n=2 n=5 n=4 n=16 
Age, years 
  Median 
 
41.5 
 
34.0 
 
35.0 
 
45.0 
 
39.5 
 
35.5 
  Range 34.0-49.0 23.0-39.0 34.0-36.0 33.0-51.0 27.0-46.0 23.0-51.0 
Female, n (%) 1 (50) 1 (33) 0 (0) 2 (40) 2 (50) 6 (38) 
Weight, kg       
  Median 49.4 65.7 70.7 58.0 63.0 60.1 
  Range 46.9-51.8 52.0-71.0 60.5-80.8 48.5-83.0 53.5-85.9 46.9-85.9 
β-thalassemia major, n (%) 2 (100) 1 (33) 2 (100) 3 (60) 4 (100) 12 (75) 
β-thalassemia intermedia*, n (%) 0 2 (67) 0 2 (40) 0 4 (25) 
Transfusion burden, RBC units/24 
weeks† 
 
15, 33 14, 18, 33 30, 30 8, 18, 18, 30, 
35 
18, 18, 18, 24 - 
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Characteristic 
Sotatercept dose  
0.1 mg/kg 
(n=8) 
0.3 mg/kg 
(n=9) 
0.5 mg/kg 
(n=8) 
0.75 mg/kg 
(n=12) 
1.0 mg/kg 
(n=9) 
Overall 
(N=46) 
Hb, g/dL 
  Median 
  Range 
 
9.5 
9.3-9.7 
 
8.6 
8.5-10.6 
 
9.8 
9.4-10.1 
 
8.9 
8.0-10.0 
 
9.6 
8.6-10.9 
 
9.3 
8.0-10.9 
NTDT: non-transfusion-dependent β-thalassemia; TDT: transfusion-dependent β-thalassemia; Hb: hemoglobin; SD: standard deviation; MCV: mean corpuscular 
volume; RBC: red blood cell. *Patients with β-thalassemia intermedia gene mutations who met the transfusion burden requirement were classified as having TDT. 
†Values presented for transfusion burden for individual TDT patients. 
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Table 2. Incidence of treatment-related AEs of any grade occurring in sotatercept-treated patients in any dose cohort. 
AEs, n (%) 
Sotatercept dose (data presented prior to intrapatient dose 
escalation) 
Overall (data 
presented post-
intrapatient 
dose 
escalation) 
(N=46) 
0.1 mg/kg 
(n=8) 
0.3 mg/kg 
(n=9) 
0.5 mg/kg 
(n=8) 
0.75 mg/kg 
(n=12) 
1.0 mg/kg 
(n=9) 
Patients with ≥1 treatment-emergent 
AE 
8 (100) 9 (100) 8 (100) 12 (100) 9 (100) 46 (100) 
Patients with ≥1 treatment-related 
AE* 
2 (25) 2 (22) 4 (50) 8 (67) 6 (67) 25 (54) 
  Bone pain 2 (25) 2 (22) 2 (25) 1 (8) 4 (44) 12 (26) 
  Arthralgia 0 0 1 (13) 3 (25) 1 (11) 7 (15) 
  Back pain 0 0 1 (13) 2 (17) 2 (22) 5 (11) 
  Asthenia/fatigue 0 0 1 (13) 3 (25) 1 (11) 5 (11) 
  Hypertension 0 0 1 (13) 2 (17) 1 (11) 5 (11) 
  Pain in extremity 0 0 1 (13) 2 (17) 0 3 (7) 
Patients with treatment-emergent 
AEs leading to discontinuation† 
2 (25) 0 1 (13) 3 (25) 2 (22) 8 (17) 
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AEs, n (%) 
Sotatercept dose (data presented prior to intrapatient dose 
escalation) 
Overall (data 
presented post-
intrapatient 
dose 
escalation) 
(N=46) 
0.1 mg/kg 
(n=8) 
0.3 mg/kg 
(n=9) 
0.5 mg/kg 
(n=8) 
0.75 mg/kg 
(n=12) 
1.0 mg/kg 
(n=9) 
Treatment-emergent AEs leading to 
discontinuation‡ 
      
  Hypertension 0 0 0 2 (17) 0 2 (4) 
  Superficial thrombophlebitis 1 (13) 0 0 0 0 1 (2) 
  Injection site erythema 0 0 0 1 (8) 0 1 (2) 
  Pyrexia 0 0 0 0 1 (11) 1 (2) 
  Extramedullary hematopoiesis 0 0 0 0 1 (11) 1 (2) 
  Ventricular extrasystoles 0 0 1 (13) 0 0 1 (2) 
  Hypersensitivity  0 0 0 1 (8) 0 1 (2) 
  Bone pain 1 (13) 0 0 0 0 1 (2) 
AEs in each dose cohort are presented prior to intrapatient dose escalation. Total AEs are presented post-intrapatient dose escalation. AE: adverse event. *AEs 
occurring in ≥5% of sotatercept-treated patients. †AEs occurring in any sotatercept-treated patient. ‡ One patient had both injection site erythema and 
hypersensitivity as AEs leading to treatment discontinuation. 
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Figure 1. Response to sotatercept treatment in patients with non-transfusion-dependent 
β-thalassemia (NTDT). (A) Percentage of sotatercept-treated NTDT patients achieving a mean 
hemoglobin (Hb) level increase from baseline of ≥1.0 g/dL and ≥1.5 g/dL sustained for ≥12 
weeks by assigned dose group. (B) Average maximum increase in Hb levels within 12 weeks 
from baseline levels in responders versus non-responders by dose group. Responders were 
those patients achieving a ≥1.0 g/dL increase in Hb levels sustained for ≥12 weeks. Error bars 
show standard deviation of the mean. 
 
Figure 2. Mean change in hemoglobin (Hb) levels from baseline up to day 400 in patients 
with non-transfusion-dependent β-thalassemia (NTDT) treated with different doses of 
sotatercept. Data are presented by assigned dose level, prior to intrapatient dose escalation. 
 
 
Figure 3. Percentage of transfusion-dependent β-thalassemia (TDT) patients treated with 
different doses of sotatercept that achieved a reduction in transfusion burden of ≥20%, 
≥33%, and ≥50% sustained for ≥24 weeks.  
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Supplemental Data 
Methods 
Exclusion criteria 
Exclusion criteria included major cardiac problems, erythropoiesis-stimulating agent use 
≤28 days prior to enrollment, history of grade ≥3 thromboembolic events, and initiation of, or 
change in, hydroxyurea treatment ≤1 year prior to enrollment. 
 
Study design 
Patients with transfusion-dependent β-thalassemia (TDT) and patients with non-transfusion-
dependent β-thalassemia (NTDT) were assigned alternately to receive either 0.1 mg/kg or 
0.3 mg/kg sotatercept (Figure S1), with the first TDT patient enrolled receiving 0.1 mg/kg and 
the first NTDT patient enrolled receiving 0.3 mg/kg. Sotatercept was provided as a lyophilized 
powder in labeled, rubber-stoppered glass vials, which was reconstituted with water for injection 
prior to administration. Each dose was administered by subcutaneous injection in the upper 
arm, abdomen, or thigh once every 21 days. Higher dose levels were opened to enrollment 
sequentially if ≤1 of 6 patients experienced a dose-limiting toxicity (DLT) ≥21 days after the last 
patient in that cohort received his or her first dose of sotatercept. A potential recommended 
dose (PRD), defined as the highest dose level at which ≤1 of 6 patients experienced a DLT, was 
to be determined based on the first 3 doses of sotatercept administered. Once the PRD was 
established, an additional 10 patients were planned to be enrolled at the PRD level (Figure S1). 
If the previous dose level studied exceeded the PRD, doses were reduced as required. The 
actual recommended dose was to be defined and assessed after review of the safety and 
efficacy data. A DLT was defined as any 1 or more of the following: grade ≥3 hypertension 
(according to National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-
CTCAE], version 4.0 available at 
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https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm), hemoglobin (Hb) 
>14 g/dL (within 7 days posttransfusion) sustained for 1 week, or any NCI-CTCAE version 4.0 
grade ≥3 toxicity related to sotatercept. 
 
Patients were scheduled to participate in the study for approximately 9 months, up to a 
maximum of 27 months. Patients were enrolled to receive up to 6 doses of sotatercept with the 
treatment period planned to last approximately 4 to 5 months, up to a maximum of 22 months, 
dependent on dose delays. Patients receiving 6 doses of sotatercept, who showed signs of 
efficacy with no dose delay or a <12-week delay between each dose, could continue treatment 
for ≤22 months (subject to investigator discretion). Upon completion of the main treatment 
phase, any patient who demonstrated clinical benefit, as assessed by the investigator, could 
continue receiving treatment under the “long-term treatment period”, up to a maximum of 
3 years. The posttreatment follow-up period was 112 days from the last dose of sotatercept. 
Dose delays were defined as a dose not administered >4 days from the planned dosing day due 
to Hb >12.5 g/dL, and/or hematocrit >40%, and/or grade ≥2 hypertension. Patients who 
discontinued prior to receiving at least 6 doses of sotatercept continued into the posttreatment 
follow-up period. Patients who did not exhibit any sign of efficacy at the primary assigned dose 
level and who completed at least 3 doses could be dose-escalated to the highest open dose 
level. Patients who showed intermittent signs of efficacy at the primary assigned dose level 
(including reduction in transfusion burden or intermittent Hb increase ≥1 g/dL compared with 
mean pretreatment Hb values but with mean on-treatment increase <1 g/dL over the previous 3 
doses) could be dose-escalated to the next higher open dose level. Patients who showed signs 
of efficacy at the primary assigned dose level but lost the response during the treatment period 
could be dose-escalated to the next higher open dose level. Intrapatient dose escalation was 
planned to be carried out once over the whole treatment period. However, after safety and 
efficacy data review, the steering committee could allow dose escalation following special 
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intrapatient dose-escalation requests such as, but not limited to, patients who had been dose-
escalated once but lost the response to treatment. 
 
During the study treatment period and the follow-up period, concomitant blood transfusions 
could be given if the patient’s Hb fell below the mean Hb value calculated based on the patient’s 
transfusion history record 168 days prior to study day 1. All transfusion decisions were at 
investigator discretion and per local practice. In order to see a rapid effect of sotatercept without 
potential confounding caused by red blood cell (RBC) transfusions, the first dose of sotatercept 
should have been administered 7-17 days after the last transfusion prior to patient enrollment 
(study day 1). For all subsequent doses, if the next planned RBC transfusion was to be 
administered on the same day as sotatercept, sotatercept administration should have occurred 
at least 24 hours after the RBC transfusion. 
 
Statistical analyses 
Demographics and baseline characteristics were analyzed by assigned dose level for the 
safety population; baseline values were the last values collected on or before the start of study 
therapy. Dose reductions/interruptions were summarized by cohort and assigned dose level, 
including patients experiencing ≥1 dose reduction/interruption and time to first dose 
reduction/interruption. 
 
All efficacy analyses were presented by assigned dose level of sotatercept. Descriptive 
statistics such as mean, minimum, median, maximum, and sample size were used to describe 
transfusion burden at baseline and during treatment. Changes in transfusion burden from 
baseline to on-treatment Hb values prior to each RBC unit transfusion were summarized for 
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transfusions received prior to sotatercept treatment and during sotatercept treatment, if 
applicable. 
 
Transfusion burden reduction from baseline to treatment was analyzed by dose level, 
based on the RBC transfusion-dependent population. Transfusion burden at baseline was 
defined as the total number of RBC units transfused within 168 days (24 weeks) prior to the first 
dose of study therapy. Transfusion burden during treatment was defined as the total number of 
RBC units transfused during the treatment divided by the treatment duration and multiplied by 
168 days. The result was a 168-day transfusion burden average. 
 
Hb levels were analyzed for both TDT and NTDT patients. Baseline Hb level was 
determined as the last Hb level measured prior to the first dose of sotatercept. Mean 
pretreatment Hb level was calculated from all Hb levels collected for a period of 168 days prior 
to study day 1. The proportion of patients with erythroid response, defined as transfusion-free 
with a Hb increase from baseline of ≥1.0 or ≥1.5 g/dL, was measured over a continuous 12-
week rolling interval during the treatment period. 
 
Safety analyses were performed on the safety population. Adverse events (AEs) were 
coded using the Medical Dictionary for Regulatory Activities (MedDRA). Treatment-emergent 
AEs were summarized by worst severity grade, system organ class, and preferred term. 
Treatment-emergent AEs leading to death or treatment discontinuation, those classified by the 
NCI CTCAE, version 4.0 as grade ≥3, those related to investigational product, and serious 
treatment-emergent AEs were summarized separately. 
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Clinical laboratory results were summarized descriptively by treatment group. Clinically 
significant hematologic and non-hematologic laboratory abnormalities were listed and 
summarized according to the NCI CTCAE, version 4.0, by treatment group. 
 
Sample size and patient allocation 
This was a dose-finding study; sample size depended on the dose levels evaluated. Up to a 
maximum of 65 patients were planned for enrollment into the study, including approximately 10 
patients who were planned for enrollment into an extended cohort to evaluate the safety and 
efficacy end points at the PRD level. 
 
A unique multi-digit patient identification number was manually assigned by site staff to 
each patient entering the treatment period. The two starting doses, 0.1 mg/kg and 0.3 mg/kg, 
were opened for enrollment in parallel, with TDT and NTDT patients assigned alternately to 
each dose level. 
 
Study locations 
Hôpital Henri Mondor, Creteil, France 
Hôpital Necker-Enfants Malades, Paris, France 
Laikon General Hospital, Athens, Greece 
Universita degli Studi Cagliari, Cagliari, Italy 
Ospedale Galliera, Genoa, Italy 
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy 
University College London Cancer Institute, London, United Kingdom 
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IRB sites and approval dates 
Name of IRB Address Date of 
Approval 
CPP Ile-de-France II Ethics Committee 
 
149, rue de Sevres   
75743 Paris  
France  
Cedex 15 Carre Necker- Porte N2 
Sep 27, 2017 
London Central Research Ethics Committee Health Research Authority  
Ground Floor, Skipton House  
80 London Rd. 
London 
SE1 6LH 
United Kingdom 
Aug 02, 2017 
Regional Ethics Committee of Liguria Largo Rosanna Benzi, 10 
16132 Genoa  
Italy 
Aug 10, 2017 
Ethics Committee - Milano Area 2 Via Francesco Sforza, 28          
20122 Milano 
Italy 
Jul 05, 2017 
Independent Ethics Committee of Azienda 
Ospedaliera Universitaria Di Cagliari 
Via Ospedale, 54                         
09124 Cagliari 
Italy 
Nov 27, 2017 
National Ethics Committee 284 Mesogeion Ave.  
15562 Cholargos 
Athens 
Greece 
Aug 02, 2017 
Scientific Council of LAIKO General Hospital 
of Athens    
17 Ag. Thoma str. 
11527 Athens 
Greece 
Aug 10, 2017 
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Table S1. Incidence of treatment-emergent AEs of any grade; AEs occurring in ≥5% of sotatercept-treated patients reported 
overall. 
AEs, n (%) 
Sotatercept dose (data presented prior to intrapatient dose 
escalation) 
Overall (data 
presented post-
intrapatient dose 
escalation) 
(N=46) 
0.1 mg/kg 
(n=8) 
0.3 mg/kg 
(n=9) 
0.5 mg/kg  
(n=8) 
0.75 mg/kg  
(n=12) 
1.0 mg/kg  
(n=9) 
Patients with ≥1 AE 8 (100) 9 (100) 8 (100) 12 (100) 9 (100) 46 (100) 
  Arthralgia 3 (38) 3 (33) 6 (75) 6 (50) 1 (11) 21 (46) 
  Asthenia/fatigue 4 (50) 1 (11) 5 (63) 6 (50) 3 (33) 20 (44) 
  Headache 0 4 (44) 4 (50) 9 (75) 1 (11) 23 (50) 
  Bone pain 3 (38) 3 (33) 4 (50) 3 (25) 4 (44) 18 (39) 
  Back pain 2 (25) 2 (22) 3 (38) 3 (25) 3 (33) 16 (35) 
  Cough 1 (13) 2 (22) 4 (50) 3 (25) 2 (22) 16 (35) 
  Pyrexia 1 (13) 5 (56) 1 (13) 3 (25) 4 (44) 15 (33) 
  Oropharyngeal pain 3 (38) 1 (11) 2 (25) 3 (25) 1 (11) 14 (30) 
  Pain in extremity 3 (38) 0 3 (38) 2 (17) 2 (22) 12 (26) 
  Hypertension 0 0 3 (38) 3 (25) 2 (22) 12 (26) 
  Dizziness 0 1 (11) 3 (38) 2 (17) 0 11 (24) 
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AEs, n (%) 
Sotatercept dose (data presented prior to intrapatient dose 
escalation) 
Overall (data 
presented post-
intrapatient dose 
escalation) 
(N=46) 
0.1 mg/kg 
(n=8) 
0.3 mg/kg 
(n=9) 
0.5 mg/kg  
(n=8) 
0.75 mg/kg  
(n=12) 
1.0 mg/kg  
(n=9) 
  Nausea 0 1 (11) 3 (38) 3 (25) 1 (11) 10 (22) 
  Myalgia 0 2 (22) 3 (38) 2 (17) 1 (11) 10 (22) 
  Upper abdominal pain 2 (25) 3 (33) 1 (13) 3 (25) 0 9 (20) 
  Influenza-like illness 1 (13) 3 (33) 2 (25) 1 (8) 0 8 (17) 
  Rhinitis 1 (13) 1 (11) 4 (50) 1 (8) 0 8 (17) 
  Neck pain 0 0 2 (25) 4 (33) 0 8 (17) 
  Upper respiratory tract infection 0 2 (22) 3 (38) 1 (8) 1 (11) 7 (15) 
  Epistaxis 0 0 0 2 (17) 3 (33) 7 (15) 
  Diarrhea 0 1 (11) 0 2 (17) 0 6 (13) 
  Musculoskeletal pain 0 2 (22) 1 (13) 2 (17) 0 6 (13) 
  Toothache 0 1 (11) 1 (13) 1 (8) 1 (11) 6 (13) 
  Increased alanine aminotransferase 1 (13) 1 (11) 1 (13) 1 (8) 1 (11) 5 (11) 
  Nasopharyngitis 1 (13) 0 2 (25) 1 (8) 0 5 (11) 
  Sinusitis 0 1 (11) 2 (25) 0 1 (11) 5 (11) 
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AEs, n (%) 
Sotatercept dose (data presented prior to intrapatient dose 
escalation) 
Overall (data 
presented post-
intrapatient dose 
escalation) 
(N=46) 
0.1 mg/kg 
(n=8) 
0.3 mg/kg 
(n=9) 
0.5 mg/kg  
(n=8) 
0.75 mg/kg  
(n=12) 
1.0 mg/kg  
(n=9) 
  Hypotension 2 (25) 0 2 (25) 0 0 5 (11) 
  Influenza 0 2 (22) 1 (13) 1 (8) 0 5 (11) 
  Amenorrhea 0 1 (11) 0 2 (17) 0 5 (11) 
  Lower abdominal pain 1 (13) 1 (11) 0 2 (17) 0 4 (9) 
  Oral herpes 1 (13) 2 (22) 0 0 0 4 (9) 
  Nasal congestion 0 2 (22) 0 1 (8) 0 4 (9) 
  Teething 0 2 (22) 1 (13) 0 0 4 (9) 
  Tinnitus 0 1 (11) 0 1 (8) 1 (11) 4 (9) 
  Musculoskeletal chest pain 0 0 0 2 (17) 0 4 (9) 
  Musculoskeletal stiffness 0 0 1 (13) 1 (8) 0 4 (9) 
  Pharyngitis 1 (13) 0 0 0 1 (11) 4 (9) 
  Vomiting  0 0 1 (13) 1 (8) 0 4 (9) 
  Dysuria 0 1 (11) 1 (13) 1 (8) 0 3 (7) 
  Dyspepsia 0 1 (11) 0 1 (8) 1 (11) 3 (7) 
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AEs, n (%) 
Sotatercept dose (data presented prior to intrapatient dose 
escalation) 
Overall (data 
presented post-
intrapatient dose 
escalation) 
(N=46) 
0.1 mg/kg 
(n=8) 
0.3 mg/kg 
(n=9) 
0.5 mg/kg  
(n=8) 
0.75 mg/kg  
(n=12) 
1.0 mg/kg  
(n=9) 
  Increased aspartate aminotransferase 0 1 (11) 0 1 (8) 1 (11) 3 (7) 
  Tachycardia  0 2 (22) 0 0 1 (11) 3 (7) 
  Abdominal pain 0 0 1 (13) 1 (8) 0 3 (7) 
  Escherichia urinary tract infection 0 0 0 0 2 (22) 3 (7) 
  Sciatica 0 1 (11) 0 1 (8) 0 3 (7) 
  Somnolence 1 (13) 0 0 1 (8) 0 3 (7) 
  Local swelling 1 (13) 0 1 (13) 0 0 3 (7) 
  Skin ulcer 1 (13) 0 1 (13) 0 0 3 (7) 
  Fall 0 1 (11) 1 (13) 0 0 3 (7) 
  Posttraumatic pain 0 0 2 (25) 0 0 3 (7) 
  Nephrolithiasis 0 1 (11) 0 0 1 (11) 3 (7) 
  Extramedullary hemopoiesis 0 0 0 0 2 (22) 3 (7) 
  Seasonal allergy 0 0 0 0 1 (11) 3 (7) 
  Decreased appetite 0 0 1 (13) 1 (8) 0 3 (7) 
AEs in each dose cohort are presented prior to intrapatient dose escalation. Total AEs are presented post-intrapatient dose escalation. AE: adverse event. 
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Table S2. Incidence of serious AEs among sotatercept-treated patients. 
Serious AEs, n (%) 
Sotatercept dose (data presented prior to intrapatient dose 
escalation) 
Overall (data 
presented post-
intrapatient dose 
escalation) 
(N=46) 
0.1 mg/kg 
(n=8) 
0.3 mg/kg 
(n=9) 
0.5 mg/kg 
(n=8) 
0.75 mg/kg 
(n=12) 
1.0 mg/kg  
(n=9) 
Patients with ≥1 serious AE 2 (25) 1 (11) 1 (13) 1 (8) 1 (11) 6 (13) 
  Bacterial prostatitis 0 0 0 1 (8) 0 1 (2) 
  Pharyngotonsillitis 0 1 (11) 0 0 0 1 (2) 
  Subcutaneous abscess 0 1 (11) 0 0 0 1 (2) 
  Pyrexia 0 1 (11) 0 0 0 1 (2) 
  Lumbar vertebral fracture 0 0 1 (13) 0 0 1 (2) 
  Bone pain 1 (13) 0 0 0 0 1 (2) 
  Syncope 0 0 0 0 1 (11) 1 (2) 
  Superficial thrombophlebitis 1 (13) 0 0 0 0 1 (2) 
AEs in each dose cohort are presented prior to intrapatient dose escalation. Total AEs are presented post-intrapatient dose escalation. AE: adverse event. 
 
12 
Table S3. Incidence of grade 3-4 treatment-emergent AEs among sotatercept-treated patients. 
Grade 3-4 treatment-emergent AEs, 
n (%) 
Sotatercept dose (data presented prior to intrapatient dose 
escalation) 
Overall (data 
presented post-
intrapatient dose 
escalation) 
(N=46) 
0.1 mg/kg 
(n=8) 
0.3 mg/kg 
(n=9) 
0.5 mg/kg  
(n=8) 
0.75 mg/kg  
(n=12) 
1.0 mg/kg  
(n=9) 
Patients with ≥1 grade 3-4 AE 1 (13) 1 (11) 1 (13) 4 (33) 2 (22) 9 (20) 
  Hypertension 0 0 0 2 (17) 0 2 (4) 
  Anemia 1 (13) 0 0 1 (8) 0 2 (4) 
  Bone pain 1 (13) 0 0 0 0 1 (2) 
  Alloimmunization 0 0 0 0 1 (11) 1 (2) 
  Asthenia/fatigue 0 0 0 1 (8) 0 1 (2) 
  Ventricular extrasystoles 0 0 1 (13) 0 0 1 (2) 
  Bacterial prostatitis 0 0 0 1 (8) 0 1 (2) 
  Hemolytic transfusion reaction 0 0 0 0 1 (11) 1 (2) 
  Increased fetal hemoglobin 0 0 0 0 1 (11) 1 (2) 
  Syncope 0 0 0 0 1 (11) 1 (2) 
  Amenorrhea  0 1 (11) 0 0 0 1 (2) 
AEs in each dose cohort are presented prior to intrapatient dose escalation. Total AEs are presented post-intrapatient dose escalation. AE: adverse event. 
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Table S4. Incidence of treatment-emergent AEs in NTDT and TDT patients treated with sotatercept; treatment-emergent AEs 
occurring in ≥5% patients overall. 
AEs, n (%) 
TDT 
(n=16) 
NTDT 
(n=30) 
Overall 
(N=46) 
Patients with ≥1 AE 16 (100) 30 (100) 46 (100) 
  Headache 7 (44) 16 (53) 23 (50) 
  Arthralgia 7 (44) 14 (47) 21 (46) 
  Asthenia/fatigue 9 (56) 11 (37) 20 (44) 
  Bone pain 10 (63) 8 (27) 18 (39) 
  Back pain 9 (56) 7 (23) 16 (34) 
  Cough 4 (25) 12 (40) 16 (35) 
  Pyrexia 5 (31) 10 (33) 15 (33) 
  Oropharyngeal pain 4 (25) 10 (33) 14 (30) 
  Pain in extremity 5 (31) 7 (23) 12 (26) 
  Hypertension 4 (25) 8 (27) 12 (26) 
  Dizziness 4 (25) 7 (23) 11 (24) 
  Nausea 4 (25) 6 (20) 10 (22) 
  Myalgia 4 (25) 6 (20) 10 (22) 
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AEs, n (%) 
TDT 
(n=16) 
NTDT 
(n=30) 
Overall 
(N=46) 
  Upper abdominal pain 4 (25) 5 (17) 9 (20) 
  Influenza-like illness 3 (19) 5 (17) 8 (17) 
  Rhinitis 2 (13) 6 (20) 8 (17) 
  Neck pain 1 (6) 7 (23) 8 (17) 
  Upper respiratory tract infection 1 (6) 6 (20) 7 (15) 
  Epistaxis 3 (19) 4 (13) 7 (15) 
  Musculoskeletal pain 2 (13) 4 (13) 6 (13) 
  Diarrhea 1 (6) 5 (17) 6 (13) 
  Toothache 4 (25) 2 (7) 6 (13) 
  Influenza 2 (13) 3 (10) 5 (11) 
  Nasopharyngitis 2 (13) 3 (10) 5 (11) 
  Increased alanine aminotransferase 2 (13) 3 (10) 5 (11) 
  Hypotension 1 (6) 4 (13) 5 (11) 
  Sinusitis 3 (19) 2 (7) 5 (11) 
  Amenorrhea 1 (6) 4 (13) 5 (11) 
  Teething 2 (13) 2 (7) 4 (9) 
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AEs, n (%) 
TDT 
(n=16) 
NTDT 
(n=30) 
Overall 
(N=46) 
  Nasal congestion 3 (19) 1 (3) 4 (9) 
  Lower abdominal pain 0 4 (13) 4 (9) 
  Tinnitus 1 (6) 3 (10) 4 (9) 
  Oral herpes 2 (13) 2 (7) 4 (9) 
  Vomiting 0 4 (13) 4 (9) 
  Pharyngitis 3 (19) 1 (3) 4 (9) 
  Musculoskeletal chest pain 1 (6) 3 (10) 4 (9) 
  Musculoskeletal stiffness 0 4 (13) 4 (9) 
  Tachycardia 1 (6) 2 (7) 3 (7) 
  Dysuria 1 (6) 2 (7) 3 (7) 
  Increased aspartate 
aminotransferase 
1 (6) 2 (7) 3 (7) 
  Dyspepsia 2 (13) 1 (3) 3 (7) 
  Escherichia urinary tract infection 0 3 (10) 3 (7) 
  Local swelling 0 3 (10) 3 (7) 
  Sciatica  0 3 (10) 3 (7) 
16 
AEs, n (%) 
TDT 
(n=16) 
NTDT 
(n=30) 
Overall 
(N=46) 
  Somnolence 2 (13) 1 (3) 3 (7) 
  Abdominal pain 0 3 (10) 3 (7) 
  Nephrolithiasis 1 (6) 2 (7) 3 (7) 
  Extramedullary hemopoiesis 2 (13) 1 (3) 3 (7) 
  Seasonal allergy 1 (6) 2 (7) 3 (7) 
  Decreased appetite 1 (6) 2 (7) 3 (7) 
  Fall 0 3 (10) 3 (7) 
  Posttraumatic pain 1 (6) 2 (7) 3 (7) 
  Skin ulcer 0 3 (10) 3 (7) 
Data presented post-intrapatient dose escalation. AE: adverse event; NTDT: non-transfusion-dependent β-thalassemia; TDT: transfusion-dependent β-
thalassemia. 
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Figure S1. Study design. 
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Figure S2. Mean (SD) change in levels of total bilirubin and indirect bilirubin from baseline during treatment with 
sotatercept. (A) Mean (SD) change in patients with non-transfusion-dependent β-thalassemia. (B) Mean (SD) change in patients 
with transfusion-dependent β-thalassemia. Data post-intrapatient dose escalation not included. SD: standard deviation. 
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Figure S3. Change in extramedullary masses (EMM) in patients with non-transfusion-dependent β-thalassemia (NTDT). (A) 
EMM at baseline (left) and at 12 months posttreatment (right) in a patient enrolled to 0.3 mg/kg sotatercept. (B) EMM at baseline 
(left) and at 7 months posttreatment (right) in a patient enrolled to 1.0 mg/kg sotatercept. Hb: hemoglobin; MCV: mean corpuscular 
volume; RBC: red blood cell. 
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Figure S4. Improvement in leg ulcers after 6 months treatment with sotatercept 0.5 mg/kg in a patient with non-transfusion-
dependent β-thalassemia (NTDT). The 51-year-old, female patient underwent a skin graft at 4.5 months posttreatment. 
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Figure S5. Change in red blood cell (RBC) morphology. (A) A 37-year-old, male patient with 
non-transfusion-dependent β-thalassemia (NTDT) treated with sotatercept 0.3 mg/kg (dose 
escalation to 0.5 mg/kg at 11 months). (B) A 54-year-old, male patient with NTDT treated with 
sotatercept 0.5 mg/kg. (C) A 65-year-old, female patient with NTDT treated with sotatercept 
0.75 mg/kg. Hb: hemoglobin. 
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Figure S6. Mean absolute serum ferritin (SF) levels. (A) Patients with non-transfusion-
dependent β-thalassemia (NTDT) receiving iron chelation therapy (ICT); (B) Patients with NTDT 
not receiving ICT; (C) Patients with transfusion-dependent β-thalassemia (TDT) receiving ICT. 
Data post-intrapatient dose escalation not included. 
  
 
